272 related articles for article (PubMed ID: 31275137)
1. AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report.
Ni D; AlZahrani F; Smylie M
Case Rep Oncol; 2019; 12(2):456-465. PubMed ID: 31275137
[TBL] [Abstract][Full Text] [Related]
2. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
[TBL] [Abstract][Full Text] [Related]
3. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.
Läubli H; Balmelli C; Bossard M; Pfister O; Glatz K; Zippelius A
J Immunother Cancer; 2015; 3():11. PubMed ID: 25901283
[TBL] [Abstract][Full Text] [Related]
4. Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report.
Dang H; Sun J; Wang G; Renner G; Layfield L; Hilli J
World J Clin Cases; 2020 Sep; 8(18):4100-4108. PubMed ID: 33024767
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab-Induced Pancytopenia: A Case Report.
Atwal D; Joshi KP; Ravilla R; Mahmoud F
Perm J; 2017; 21():17-004. PubMed ID: 28746020
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab use for the treatment of advanced melanoma.
Specenier P
Expert Opin Biol Ther; 2017 Jun; 17(6):765-780. PubMed ID: 28323504
[TBL] [Abstract][Full Text] [Related]
7. Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report.
Ogawa K; Ito J; Fujimoto D; Morita M; Yoshizumi Y; Ariyoshi K; Tomii K; Katakami N
Invest New Drugs; 2018 Jun; 36(3):509-512. PubMed ID: 29340837
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
9. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab-induced Myositis in the Setting of Metastatic Melanoma: An Increasingly Common Phenomenon.
Swali R
J Clin Aesthet Dermatol; 2020 Jun; 13(6):44-45. PubMed ID: 32884619
[TBL] [Abstract][Full Text] [Related]
11. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
13. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
Hanna KS
Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999
[TBL] [Abstract][Full Text] [Related]
14. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Afzal MZ; Shirai K
J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy-associated autoimmune hemolytic anemia.
Khan U; Ali F; Khurram MS; Zaka A; Hadid T
J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review.
Tanios GE; Doley PB; Munker R
Eur J Haematol; 2019 Feb; 102(2):157-162. PubMed ID: 30347480
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
18. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
19. Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma.
Bari O; Cohen PR
Cureus; 2017 Feb; 9(2):e1026. PubMed ID: 28348944
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab in the management of metastatic melanoma.
Spain L; Younger E; Hatipoglu E; Larkin J
Melanoma Manag; 2015 Nov; 2(4):315-325. PubMed ID: 30190860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
